v3.26.3
SHAREHOLDERS' EQUITY (Tables)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Schedule of fair value for options granted
   

Nine Months Ended

September 30,

 
    2026     2025  
Expected volatility     95.1 %     102.5 %
Risk-free rate     4.1 %     4.1 %
Dividend yield     -       -  
Expected term (in years)     6.08       6.25  
Share price   $ 6.53     $ 1.04  
Schedule of stock options activity
    Number    

Weighted

average

exercise

price

   

Weighted

average

remaining

contractual

life (years)

   

Aggregate

intrinsic

value (in

thousands)

 
Options outstanding as of December 31, 2025     52,450     $ 13.86       9.43     $ -  
Granted     212,692       6.53       -       -  
Exercised     -       -       -       -  
Forfeited     (198,025 )     10.67       -       -  
Options outstanding as of September 30, 2026     67,117     $ 9.75       8.16     $ 2.8  
                                 
Options exercisable as of September 30, 2026     13,060     $ 20.87       3.30     $ -  
Schedule of employee and non-employee RSUs activity
   

Number of

shares

underlying

outstanding

RSUs

   

Weighted-

average

grant date

fair value

 
Unvested RSUs as of December 31, 2025     73,433     $ 15.30  
Granted     118,506       7.04  
Vested     (29,593 )     16.41  
Forfeited     (30,033 )     11.34  
Unvested RSUs as of September 30, 2026     132,313     $ 8.55  
Schedule of options and RSUs outstanding
Range of exercise price    

Options and RSUs

outstanding as of

September 30, 2026

   

Weighted

average

remaining

contractual

life (years) (1)

   

Options outstanding and

exercisable as of

September 30, 2026

   

Weighted

average

remaining

contractual

life (years) (1)

 
  RSUs       132,313       -       -       -  
  Options:                                  
$ 6.53       39,994       9.49       -       -  
$ 8.6       18,750       8.87       4,687       8.87  
$ 14.70       8,333       0.17       8,333       0.17  
$ 2,257.5-$4,200       40       1.33       40       1.33  
            199,430       8.16       13,060       3.30  

 

  (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of non-cash share-based compensation expense
   

Nine Months Ended

September 30,

 
    2026     2025  
Cost of revenues   $ 10     $ 9  
Research and development, net     104       105  
Sales and marketing     99       203  
General and administrative     329       259  
Total   $ 542     $ 576  
Schedule of warrants outstanding and exercisable
Issuance date  

Warrants

outstanding

   

Exercise price

per warrant

   

Warrants

outstanding

and

exercisable

   

Contractual 

term 

    (number)           (number)      
September 29, 2021 (1)     95,314     $ 168.00       95,314     March 29, 2027
January 8, 2025 (2)     151,514     $ 33.00       151,514     January 10, 2028
January 8, 2025 (3)     9,088     $ 41.25       9,088     January 10, 2028
June 26, 2025 (4)     333,328     $ 7.8       333,328     June 26, 2030
June 26, 2025 (5)     20,000     $ 9.75       20,000     June 26, 2030
March 25, 2026 (6)     3,148,147     $ 5.40       3,148,147     March 25, 2031
March 25, 2026 (7)     1,006,113     $ 0.0001       1,006,113     No expiration
      4,763,504               4,763,504